NCT04113811

Microwave Needle Thermoablation for Treatment of Localized Prostate Cancer

Completed NA Last updated 7 May 2025

What this trial tests

NA trial testing Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France) in Prostate Cancer in 30 participants. Completed in 11 April 2023.

Timeline

8 October 2019

Primary endpoint
16 February 2023

11 April 2023

Quick facts

Lead sponsor	Chinese University of Hong Kong
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	8 October 2019
Primary completion	16 February 2023
Estimated completion	11 April 2023
Sites	1 location across Hong Kong

Drugs / interventions tested

• Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France)

Conditions studied

• Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Chinese University of Hong Kong

Who can join

Adults 45 to 75, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Conventional treatment options for localized prostate cancer include prostatectomy, radiotherapy and active surveillance. However, prostatectomy and radiotherapy carry certain degree of morbidity, including the risks of urinary incontinence, erectile dysfunction and injury to the surrounding organs like rectum and bladder. Active surveillance carries the risk of disease progression and psychological distress to the patients. Focal therapy employs the concept of only destroying the target lesion without treating other benign areas, resulting in disease cure in majority of cases with less treatment morbidity. Microwave treatment to the prostate has been performed since more than 20 years ago for benign prostatic hyperplasia and is approved by FDA in United States. It exerts its effect through thermal destruction of prostate tissue. Targeted treatment of localized prostate cancer using microwave needle ablation guided by MRI and Ultrasound imaging has been performed recently and was shown to be safe and effective. Our study aims to assess the effectiveness of this focal therapy in treating localized prostate cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Focal ablation therapy presents promising results for selectively localized prostate cancer patients.
   Feng D, Li D, Xiao Y, Wu R, et al · · 2023 · cited 22× · PMID 37691892 · DOI 10.21147/j.issn.1000-9604.2023.04.08
2. Targeted Microwave Ablation for Prostate Cancer Under Magnetic Resonance Imaging-Ultrasound Fusion and Organ-based Tracking: Final Results from the First Phase 2 Trial (TMA-HK).
   Chiu PK, Liu AQ, Yee CH, Wong HF, et al · · 2025 · cited 1× · PMID 39689992 · DOI 10.1016/j.euo.2024.11.013